VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA, Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA, Eva POLAKOVA, Eva HANSVENCLOVA, Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ a Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2021, roč. 333, June 2021, s. 127-132. ISSN 0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy
Autoři VESELKA, Josef (203 Česká republika, garant), Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA (203 Česká republika), Maksim KASHTANOV, Maciej DABROWSKI, Peter Riis HANSEN, Hubert SEGGEWISS, Jiri BONAVENTURA (203 Česká republika), Eva POLAKOVA (203 Česká republika), Eva HANSVENCLOVA (203 Česká republika), Henning BUNDGAARD, Jurrien TEN BERG, Rodney Hilton STABLES, Jiří JARKOVSKÝ (203 Česká republika, domácí) a Morten Kvistholm JENSEN.
Vydání International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2021, 0167-5273.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.039
Kód RIV RIV/00216224:14110/21:00123837
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ijcard.2021.02.056
UT WoS 000730511500028
Klíčová slova anglicky Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 24. 7. 2023 12:58.
Anotace
Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.
VytisknoutZobrazeno: 16. 7. 2024 20:53